A non-clinical comparative study of IL-23 antibodies in psoriasis

• मुख्य लेखकों: Li Zhou (लेखक), Yibing Wang (लेखक), Qi Wan (लेखक), Fei Wu (लेखक), Jeffrey Barbon (लेखक), Robert Dunstan (लेखक), Stephen Gauld (लेखक), Mark Konrad (लेखक), Laura Leys (लेखक), Richard McCarthy (लेखक), Marian Namovic (लेखक), Christine Nelson (लेखक), Gary Overmeyer (लेखक), Denise Perron (लेखक), Zhi Su (लेखक), Leyu Wang (लेखक), Susan Westmoreland (लेखक), Jun Zhang (लेखक), Rui Zhu (लेखक), Geertruida Veldman (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Taylor & Francis Group, 2021-01-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Four antibodies that inhibit interleukin (IL)-23 are approved for the treatment of moderate-to-severe plaque psoriasis. Here, we present non-clinical data comparing ustekinumab, guselkumab, tildrakizumab and risankizumab with regard to thermostability, IL-23 binding affinity, inhibitory-binding mode...